Ben van Hout

Best Publications

• Interim Scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L Value Sets

  Ben Van Hout;M. F. Janssen;You-Shan Feng;Thomas Kohlmann

  2158
  Citations

• Valuing health-related quality of life: An EQ-5D-5L value set for England.

  Nancy J. Devlin;Koonal K. Shah;Yan Feng;Brendan Mulhern;Brendan Mulhern

  1421
  Citations

• Clinical and Economic Impact of Diabetes Mellitus on Percutaneous and Surgical Treatment of Multivessel Coronary Disease Patients Insights From the Arterial Revascularization Therapy Study (ARTS) Trial

  Alexandre Abizaid;Marco A. Costa;Marinella Centemero;Andrea S. Abizaid

  477
  Citations

• A Program of Methodological Research to Arrive at the New International EQ-5D-5L Valuation Protocol

  Mark Oppe;Nancy J. Devlin;Ben van Hout;Paul F.M. Krabbe

  460
  Citations

• Quality of Life after PCI with Drug-Eluting Stents or Coronary-Artery Bypass Surgery

  David J. Cohen;Ben Van Hout;Patrick W. Serruys;Friedrich W. Mohr

  337
  Citations

• Overview, Update, and Lessons Learned From the International EQ-5D-5L Valuation Work: Version 2 of the EQ-5D-5L Valuation Protocol.

  Elly Stolk;Kristina Ludwig;Kim Rand;Ben van Hout

  332
  Citations

• International Regulations and Recommendations for Utility Data for Health Technology Assessment

  Donna Rowen;Ismail Azzabi Zouraq;Helene Chevrou-Severac;Ben van Hout

  192
  Citations

• Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease.

  Gregg C. Fonarow;Anthony C. Keech;Terje R. Pedersen;Robert P. Giugliano

  166
  Citations

• Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis.

  Philippe Beutels;W. John Edmunds;Fernando Antoñanzas;G. Ardine De Wit

  129
  Citations

• A Comparison of Methods for Converting DCE Values onto the Full Health-Dead QALY Scale:

  Donna Rowen;John Brazier;Ben Van Hout

  123
  Citations

• Cost‐Effectiveness of LDL‐C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States

  Shravanthi R. Gandra;Guillermo Villa;Gregg C. Fonarow;Mickael Lothgren

  106
  Citations

• Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets.

  Brendan Mulhern;Yan Feng;Koonal Shah;Mathieu F Janssen

  103
  Citations

• Estimating Preference-Based Single Index Measures for Dementia Using DEMQOL and DEMQOL-Proxy

  Donna Rowen;Brendan Mulhern;Sube Banerjee;Ben van Hout

  99
  Citations

• Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.

  Gerd Laux;Bart M. S. Heeg;Ben A. van Hout;Angelika Mehnert

  92
  Citations

• Updated cost-effectiveness analysis of evolocumab in patients with very high-risk atherosclerotic cardiovascular disease

  Gregg C. Fonarow;Ben van Hout;Guillermo Villa;Jorge Arellano

  89
  Citations

• New methods for modelling EQ-5D-5L value sets: An application to English data.

  Yan Feng;Nancy J. Devlin;Koonal K. Shah;Brendan Mulhern;Brendan Mulhern

  86
  Citations

• Optimal allocation of resources over health care programmes: dealing with decreasing marginal utility and uncertainty.

  Maiwenn J Al;Talitha L Feenstra;Ben A van Hout

  81
  Citations

• A COMPARISON OF ALTERNATIVE VARIANTS OF THE LEAD AND LAG TIME TTO

  Nancy Devlin;Ken Buckingham;Koonal Shah;Aki Tsuchiya

  77
  Citations

• Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada.

  P. S. Chue;Bart M. S. Heeg;Erik Buskens;Ben A. van Hout

  72
  Citations

• Economic outcomes of percutaneous coronary intervention with drug‐eluting stents versus bypass surgery for patients with left main or three‐vessel coronary artery disease: One‐year results from the SYNTAX trial

  David J. Cohen;Tara A. Lavelle;Ben Van Hout;Haiyan Li

  70
  Citations